RE: Comments invited...
I think realistically, you have a case of "who cares" and I will explain.
You have a canadian biotech trading under $1.00 with minimal revenues and minimal profits.
1. Tons of biotechs out there that have better stories and better financials.
If you research the company, you know that the company has:
A large partnered potenital blockbuster cancer drug that could come to market in 3 years.
A vaccine for a dangerous ecoli bacteria that could get FDA approval in the U.S. and they have the manufacturing capabilities to mass produce this drug as well as others.
All of these are "MAYBE FUTURE OPPORTUNITIES"
The present day story is a built but unvalidated manufacting plant not producing revenue. A potentially great cancer drug but we won't know for 2/3 years. Some revenue from animal health and a large cash burn because of the manufacturing plant and loans outstanding to the canadian government.
It can be hard for some people to buy this story when it is 1/2 years away. Plus if your an analyst or institution, you ask the company: "Are you a human health company or an animal company?"